Fulgent Pharma
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4399 Santa Anita Ave, El Monte, Californ...Phone Number
(626) 434-8896Website
www.fulgentpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Fulgent Pharma
Fulgent Pharma is a clinical stage pharmaceutical company dedicated to developing and commercializing innovative cancer therapeutics. Their pipeline features improved chemotherapy drugs through nanoencapsulation and new drug candidates aimed at treating various cancers, including breast, lung, and pancreatic cancer. The company's lead asset, FID-007, is a nanoencapsulated paclitaxel that enhances drug efficacy while reducing toxicity, currently undergoing clinical trials. Fulgent Pharma's patented technology aims to improve drug delivery and safety, making it suitable for combination therapies.Explore more
Fulgent Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Fulgent Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Fulgent Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Fulgent Pharma has new funding data
Earning: See what the market has to say on Fulgent Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Fulgent Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Fulgent Pharma
Check if Fulgent Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Fulgent Pharma is spiking on competitors!
Fulgent Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Fulgent Pharma
Compare insights from companies similar to Fulgent Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Fulgent Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Fulgent Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Fulgent Pharma.
Fulgent Pharma Tech Stack
A closer look at the technologies used by Fulgent Pharma
Fulgent Pharma News & Media
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois. Details of the presentation are as follows: AbstractMoffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
TAMPA, Fla. & LOS ANGELES--(BUSINESS WIRE)--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration combines Moffitt’s cutting-edge clinical capabFulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, announced today that it has completed an acquisition of Fulgent Pharma Holdings, Inc. (“Fulgent Pharma”), an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments. Under the terms of the agreement, Fulgent GeANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies
NEWARK, Del.--(BUSINESS WIRE)--ANP Technologies, in Partnership with Fulgent Pharma, Teams with Moffitt Cancer Center to Develop a New Class of Leukemia Therapies.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Fulgent Pharma
Sign Up For FreeTo access detailed company insights
Fulgent Pharma is a clinical stage pharmaceutical company dedicated to developing and commercializing innovative cancer therapeutics. Their pipeline features improved chemotherapy drugs through nanoencapsulation and new drug candidates aimed at treating various cancers, including breast, lung, and pancreatic cancer. The company's lead asset, FID-00... Read More
